Skip to main content

Table 2 Adverse events (n = 17)

From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Adverse Event

Grade 1

Grade 2

Grade 3

Grade 4

Hematology

 Anemia

3

2

4

0

 Leukopenia

4

1

1

0

 Lymphopenia

0

2

1

1

 Neutropenia

0

0

1

0

 Thrombocytopenia

3

0

1

0

Gastrointestinal Disorders

 Abdominal pain

1

0

0

0

 Anorexia

1

1

0

0

 AST increased

1

0

0

0

 Bloating

0

1

0

0

 Dysgeusia

0

1

0

0

 Dyspepsia

2

0

0

0

 Diarrhea

6

3

0

0

 Nausea

8

1

2

0

 Oral mucositis

0

1

1

0

 Vomiting

6

0

1

0

Cardiovascular

 Hypertension

0

0

1

0

Infection

 Lung

0

0

1

0

 Tenosynovitis

0

0

1

0

 Urinary tract

0

1

0

0

Endocrine and Chemistry

 Hypothyroidism

0

1

0

0

Nervous System

 Dizziness

1

0

0

0

 Headache

1

0

0

0

 Paresthesia

1

0

0

0

 Syncope

0

0

1

0

Respiratory, Thoracic, and Mediastinal

 Dyspnea

1

0

0

0

 Cough

1

1

0

0

Eye Disorders

 Blurred vision

1

0

0

0

 Optic nerve disorder

0

1

0

0

Ear and Labyrinth Disorders

 Hearing impairment

0

1

1

0

 Tinnitus

1

0

0

0

General

 Fatigue

1

2

1

0

 Edema, limbs

1

0

0

0

 Localized edema

1

0

0

0

 Pain, extremity

0

1

0

0

 Weight loss

1

0

0

0

Musculoskeletal and Connective Tissue

 Arthralgia

2

0

0

0

 Arthritis

0

1

0

0

 Myalgia

2

0

0

0

 Musculoskeletal/connective tissue, leg cramps

1

1

0

0

 Musculoskeletal/connective tissue, muscle cramps

0

0

1

0

 Muscle weakness, lower limb

0

0

1

0

Skin, Subcutaneous Tissue

 Erythema

1

0

0

0

 Pruritis

1

0

0

0

 Rash, maculopapular

2

0

0

0

Metabolism and Nutrition

 Dehydration

0

1

0

0